One-Year Follow-Up of Combined Customized Therapy. Photodynamic Therapy and Bevacizumab for Exudative Age-Related Macular Degeneration

Mataix, Jorge; Desco, M Carmen; García-Pous, Maria; Palacios, E.

doi:10.1097/iae.0b013e31818a1fd3

Cited by 15 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous series of our study, comprising 63 cases with a 12-month follow-up, 18 we obtained a gain of 5.7 letters with a mean of 1.4 PDTs and 2 bevacizumab doses per patient compared with the 7.2 letters with 1.2 PDT and 2.3 ranibizumab intravitreal injections in this series. The loss and gain rates of vision are practically the same except for the group of patients with visual gains of .15 letters, which is better with PDT + ranibizumab (19% as opposed to 32.7%).…”

Section: Discussionmentioning

confidence: 81%

Combined Ranibizumab and Photodynamic Therapy to Treat Exudative Age-Related Macular Degeneration

Mataix¹,

Palacios²,

Carmen³

et al. 2010

Retina

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 81%

Combined Ranibizumab and Photodynamic Therapy to Treat Exudative Age-Related Macular Degeneration

Mataix¹,

Palacios²,

Carmen³

et al. 2010

Retina

Self Cite

View full text Add to dashboard Cite

show abstract

“…Mean numbers of retreatment per eye were 0.57 during the 12 month follow up. Navea et al treated 63 patients using bevacizumab intravitreal injection followed by PDT for 12 months [16]. The mean numbers for additional PDT and additive bevacizumab injections per patient were 0.46 and 1.0, respectively.…”

Section: Discussionmentioning

confidence: 99%

“…Several uncontrolled studies and case series have shown anatomical improvement and moderate vision gain when bevacizumab was used as a monotherapy [8-12]. However, repeated intravitreal injections are subject to the risk of complications, discomfort for the patient, and increased health care expense [13-16]. …”

mentioning

confidence: 99%

Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Kim

Lee

et al. 2011

Korean J Ophthalmol

View full text Add to dashboard Cite

PurposeTo evaluate the outcome of a combined photodynamic therapy and intravitreal injection of bevacizumab in choroidal neovascularization secondary to age-related macular degeneration.MethodsPhotodynamic therapy (PDT) was administered to 28 eyes followed by 3 consecutive bevacizumab injections. Patients were followed-up for more than 12 months. At baseline, 1, 3, 6, and 12 months post PDT, visual acuity (VA) and central macular thickness were measured using optical coherence tomography.ResultsThe mean VA was significantly improved from logarithm of the minimal angle of resolution 0.86 at baseline to 0.69 at 1 month (p = 0.011), 0.63 at 3 months (p = 0.003), 0.64 at 6 months (p = 0.004) and 0.60 at 12 months (p < 0.001). Central macular thickness decreased significantly from 328.3 µm at baseline to 230.0 µm at 6 months and 229.9 µm at 1 year (p < 0.001). Reinjection mean number was 0.4 for 6 months and 0.8 for 12 months. By 1 year, retreatment was performed in 10 eyes (36%).ConclusionsPDT combined with three consecutive intraviteal bevacizumab injections was effective in improving VA and reducing central macular thickness.

show abstract

“…In particular, over the last few years, the anti-CNV therapies evolved from protocols aimed at stabilizing a patient’s vision ( i.e ., quarterly execution of PDT-V procedure) [ 11 , 14 , 15 , 16 , 17 ], to treatments capable of improving visual acuity ( i.e ., monthly or as-needed intravitreal administration of anti-VEGF drugs) [ 12 , 13 , 18 , 19 , 20 , 21 , 22 ]. After all, considering not only the visual benefit and its maintenance but also a lower re-treatment frequency and optimization of health resource employment, positive outcomes are observed when PDT-V is combined with anti-VEGF regimens [ 6 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 ].…”

Section: Introductionmentioning

confidence: 99%

Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration

Parmeggiani

Costagliola

Semeraro

et al. 2015

IJMS

View full text Add to dashboard Cite

Macular degenerations represent leading causes of central blindness or low vision in developed countries. Most of these severe visual disabilities are due to age-related macular degeneration (AMD) and pathologic myopia (PM), both of which are frequently complicated by subfoveal choroidal neovascularization (CNV). Photodynamic therapy with verteporfin (PDT-V) is still employed for CNV treatment in selected cases or in combined regimen. In Caucasian patients, the common polymorphism G185T of factor XIII-A gene (FXIII-A-G185T; rs5985) has been described as predictor of poor angiographic CNV responsiveness to PDT-V. Nevertheless, the prognostic implications of this pharmacogenetic determinant on long-term visual outcome after a PDT-V regimen have not been evaluated. We retrospectively selected Caucasian patients presenting with treatment-naive CNV and receiving standardized PDT-V protocol for two years. The study population included patients affected by subfoveal CNV secondary to AMD or PM. We assessed the correlations between the polymorphic allele T of FXIII-A-G185T and: (1) total number of photodynamic treatments; and (2) change in visual acuity from baseline to the end of the follow-up period. Considering a total study population of 412 patients with neovascular AMD or PM, the carriers of 185 T-allele of FXIII-A (GT or TT genotype) received a higher number of photodynamic treatments than patients without it (GG wild-type genotype) (p < 0.01; mean number of PDT-V: 5.51 vs. 3.76, respectively). Moreover, patients with 185 T-allele of FXIII-A had a more marked worsening of visual acuity at 24 months than those with the GG-185 wild genotype (p < 0.01; mean difference in logMAR visual acuity: 0.22 vs. 0.08, respectively). The present findings show that the G185T polymorphism of the FXIII-A gene is associated with significant differences in the long-term therapeutic outcomes of patients treated with standardized PDT-V protocol. The comprehensive appraisal of both anti-thrombophilic effects due to FXIII-A G185T variant and photo-thrombotic action of PDT-V toward CNV provides several clues about the rationale of this intriguing pharmacogenetic correlation. Further investigations are warranted to outline the appropriate paradigm for guiding PDT-V utilization in the course of the combined therapeutic protocol for neovascular macular degeneration.

show abstract

One-Year Follow-Up of Combined Customized Therapy. Photodynamic Therapy and Bevacizumab for Exudative Age-Related Macular Degeneration

Abstract: Combined, customized PDT + Bevacizumab therapy makes it possible to obtain visual results similar to those obtained in monotherapy, but with fewer intravitreal injections. It appears to be an interesting option for this type of patients.

Cited by 15 publications

References 18 publications

Combined Ranibizumab and Photodynamic Therapy to Treat Exudative Age-Related Macular Degeneration

Combined Ranibizumab and Photodynamic Therapy to Treat Exudative Age-Related Macular Degeneration

Combined Treatment of Photodynamic Therapy and Bevacizumab for Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration

Contact Info

Product

Resources

About